Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q4G0J3

UPID:
LARP7_HUMAN

ALTERNATIVE NAMES:
La ribonucleoprotein domain family member 7; P-TEFb-interaction protein for 7SK stability

ALTERNATIVE UPACC:
Q4G0J3; B2ZHN6; Q3B7A9; Q9P1S7; Q9Y3Z8

BACKGROUND:
The La ribonucleoprotein domain family member 7, also known as LARP7, is integral to the regulation of gene expression. It binds distinct snRNAs, regulating their processing and function. As a core component of the 7SK RNP complex, LARP7 inhibits transcription elongation by RNA polymerase II. It also plays a critical role in mRNA splicing fidelity by promoting U6 snRNA processing and 2'-O-methylation, crucial for accurate splicing.

THERAPEUTIC SIGNIFICANCE:
Given LARP7's critical role in Alazami syndrome, a condition marked by severe growth restriction and intellectual disability, exploring its functions further could lead to novel therapeutic approaches. Understanding the role of LARP7 could open doors to potential therapeutic strategies, offering hope for patients with Alazami syndrome and possibly other related genetic conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.